CIB2 and ovarian cancer: For example, recently, Zhu et al. [75] found that a calcium and integrin binding protein CIB2 proved to be a novel and valuable target, which downregulated SphK1 signaling in ovarian cancer, suggesting CIB2 as a new therapeutic SphK1-targeted candidate for ovarian cancer.